Business
electroCore Regains Compliance with Nasdaq Listing Requirements
ROCKAWAY, N.J., March 07, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today
About this update from Electrocore, Inc.
[{"type":"text","content":"ROCKAWAY, N.J., March 07, 2023 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that it has received notice from the Listing Qualifications Department of the Nasdaq Stock Market LLC (Nasdaq) by letter dated March 6, 2023 informing electroCore that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2). The closing bid price of the Company’s common stock on the Nasdaq Capital Market was greater than $1.00 per share for 10 consecutive trading days between February 15, 2023 and March 1, 2023. As a result of regaining compliance, the Company’s common stock will continue to be listed on the Nasdaq Capital Market.About electroCore, Inc.electroCore, Inc. is a commercial stage bioelectronic medicine and wellness company dedicated to improving health through its non-invasive vagus nerve stimulation (“nVNS”) technology platform. Our focus is the commercialization of medical devices for the management and treatment of certain medical conditions and consumer product offerings utilizing nVNS to promote general wellbeing and human performance in the United States and select overseas markets.For more information, visit www.electrocore.com.Forward-Looking StatementsThis press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore’s business prospects and clinical and product development plans; its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments; business prospects around its wellness and human performance offerings and other new products and markets, its listing on the Nasdaq Capital Market, and other statements that are not historical in nature, particularly those that utilize terminology such as \"anticipates,\" \"will,\" \"expects,\" \"believes,\" \"intends,\" and other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, ...